235 related articles for article (PubMed ID: 25806830)
21. Prophylactic treatment with levosimendan: a retrospective matched-control study of patients with reduced left ventricular function.
Kolseth SM; Nordhaug DO; Stenseth R; Sellevold O; Kirkeby-Garstad I; Wahba A
Eur J Cardiothorac Surg; 2009 Dec; 36(6):1024-30. PubMed ID: 19592266
[TBL] [Abstract][Full Text] [Related]
22. Levosimendan improves hemodynamic status in critically ill patients with severe aortic stenosis and left ventricular dysfunction: an interventional study.
García-González MJ; Jorge-Pérez P; Jiménez-Sosa A; Acea AB; Lacalzada Almeida JB; Ferrer Hita JJ
Cardiovasc Ther; 2015 Aug; 33(4):193-9. PubMed ID: 25959786
[TBL] [Abstract][Full Text] [Related]
23. The prolonged lowering effect of levosimendan on brain natriuretic peptide levels in patients with decompansated heart failure: clinical implications.
Celik T; Iyisoy A; Yuksel UC; Kardesoglu E
Int J Cardiol; 2008 Aug; 128(1):97-9; authr reply 100-2. PubMed ID: 18501448
[TBL] [Abstract][Full Text] [Related]
24. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure.
Lilleberg J; Laine M; Palkama T; Kivikko M; Pohjanjousi P; Kupari M
Eur J Heart Fail; 2007 Jan; 9(1):75-82. PubMed ID: 16829185
[TBL] [Abstract][Full Text] [Related]
25. A dose-response study of levosimendan in a porcine model of acute ischaemic heart failure.
Kolseth SM; Wahba A; Kirkeby-Garstad I; Aro S; Nordgaard H; Høydal M; Rognmo Ø; Nordhaug D
Eur J Cardiothorac Surg; 2012 Jun; 41(6):1377-83. PubMed ID: 22219475
[TBL] [Abstract][Full Text] [Related]
26. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients.
Kyrzopoulos S; Adamopoulos S; Parissis JT; Rassias J; Kostakis G; Iliodromitis E; Degiannis D; Kremastinos DT
Int J Cardiol; 2005 Mar; 99(3):409-13. PubMed ID: 15771921
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic-pharmacodynamic interrelationships of intravenous and oral levosimendan in patients with severe congestive heart failure.
Põder P; Eha J; Sundberg S; Antila S; Heinpalu M; Loogna I; Planken U; Rantanen S; Lehtonen L
Int J Clin Pharmacol Ther; 2003 Aug; 41(8):365-73. PubMed ID: 12940594
[TBL] [Abstract][Full Text] [Related]
28. Safety and effectiveness of levosimendan in patients with predominant right heart failure.
Poelzl G; Zwick RH; Grander W; Metzler B; Jonetzko P; Frick M; Ulmer H; Pachinger O; Roithinger FX
Herz; 2008 Jul; 33(5):368-73. PubMed ID: 18773157
[TBL] [Abstract][Full Text] [Related]
29. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.
Nieminen MS; Akkila J; Hasenfuss G; Kleber FX; Lehtonen LA; Mitrovic V; Nyquist O; Remme WJ
J Am Coll Cardiol; 2000 Nov; 36(6):1903-12. PubMed ID: 11092663
[TBL] [Abstract][Full Text] [Related]
30. Effect of levosimendan on E/E' ratio in patients with ischemic heart failure.
Duygu H; Ozerkan F; Nalbantgil S; Zoghi M; Akilli A; Akin M; Nazli C; Ergene O
Int J Cardiol; 2008 Jan; 123(2):201-3. PubMed ID: 17316845
[TBL] [Abstract][Full Text] [Related]
31. Usefulness of dobutamine-induced changes of the two-dimensional longitudinal deformation predict clinical and neurohumoral improvement in men after levosimendan treatment in acutely decompensated chronic heart failure.
Paraskevaidis IA; Bistola V; Ikonomidis I; Parissis JT; Papadopoulos C; Filippatos G; Kremastinos DT
Am J Cardiol; 2008 Nov; 102(9):1225-9. PubMed ID: 18940297
[TBL] [Abstract][Full Text] [Related]
32. Planned repetitive use of levosimendan for heart failure in cardiology and internal medicine in Sweden.
Thorvaldsen T; Benson L; Hagerman I; Dahlström U; Edner M; Lund LH
Int J Cardiol; 2014 Jul; 175(1):55-61. PubMed ID: 24820737
[TBL] [Abstract][Full Text] [Related]
33. Acute effects of levosimendan on mitral regurgitation and diastolic function in patients with advanced chronic heart failure.
Branzi G; Malfatto G; Villani A; Ciambellotti F; Revera M; Giglio A; Rosa FD; Facchini M; Parati G
J Cardiovasc Med (Hagerstown); 2010 Sep; 11(9):662-8. PubMed ID: 20613551
[TBL] [Abstract][Full Text] [Related]
34. Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure.
Parissis JT; Karavidas A; Bistola V; Arapi S; Paraskevaidis IA; Farmakis D; Korres D; Filippatos G; Matsakas E; Kremastinos DT
Atherosclerosis; 2008 Mar; 197(1):278-82. PubMed ID: 17568589
[TBL] [Abstract][Full Text] [Related]
35. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
Follath F
Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
[TBL] [Abstract][Full Text] [Related]
36. The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine.
Avgeropoulou C; Andreadou I; Markantonis-Kyroudis S; Demopoulou M; Missovoulos P; Androulakis A; Kallikazaros I
Eur J Heart Fail; 2005 Aug; 7(5):882-7. PubMed ID: 15921958
[TBL] [Abstract][Full Text] [Related]
37. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
Cleland JG; Nikitin N; McGowan J
Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
[TBL] [Abstract][Full Text] [Related]
38. Levosimendan produces an additional clinical and hemodynamic benefit in patients with decompensated heart failure successfully submitted to a fluid removal treatment.
Giglioli C; Cecchi E; Landi D; Chiostri M; Spini V; Valente S; Gensini GF; Romano SM
Congest Heart Fail; 2012; 18(1):47-53. PubMed ID: 22277178
[TBL] [Abstract][Full Text] [Related]
39. Levosimendan infusion improves haemodynamics in elderly heart failure patients undergoing urgent hip fracture repair.
Ponschab M; Hochmair N; Ghazwinian N; Mueller T; Plöchl W
Eur J Anaesthesiol; 2008 Aug; 25(8):627-33. PubMed ID: 18405408
[TBL] [Abstract][Full Text] [Related]
40. Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy.
Pölzl G; Altenberger J; Baholli L; Beltrán P; Borbély A; Comin-Colet J; Delgado JF; Fedele F; Fontana A; Fruhwald F; Giamouzis G; Giannakoulas G; Garcia-González MJ; Gustafsson F; Kaikkonen K; Kivikko M; Kubica J; von Lewinski D; Löfman I; Malfatto G; Manito N; Martínez-Sellés M; Masip J; Merkely B; Morandi F; Mølgaard H; Oliva F; Pantev E; Papp Z; Perna GP; Pfister R; Piazza V; Bover R; Rangel-Sousa D; Recio-Mayoral A; Reinecke A; Rieth A; Sarapohja T; Schmidt G; Seidel M; Störk S; Vrtovec B; Wikström G; Yerly P; Pollesello P
Int J Cardiol; 2017 Sep; 243():389-395. PubMed ID: 28571618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
